Asterias Biotherapeutics (AST) Commences Dosing of First Patient in AST-OPC1 Clinical Trial
Tweet Send to a Friend
Asterias Biotherapeutics, Inc. (NYSE: AST) announced that the first patient with incomplete AIS-B cervical spinal cord injury was successfully dosed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE